首页 Axsome Therapeutics(usAXSM)-基本信息

Axsome Therapeutics(usAXSM)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:52.6

最高价:53.56

成交量:251236.0

昨收价:52.6

最低价:51.68

最新价:53.44

行情图标
概要信息

英文名称:Axsome Therapeutics


简介:Axsome Therapeutics, Inc.成立于2012年1月


电话:1-212-3323241


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Axsome Therapeutics, Inc.是一家临床阶段的生物制药公司,开发管理及治疗疼痛和其他中枢神经系统疾病的疗法。Axsome Therapeutics候选产品包含: AXS-02,用于复杂局部疼痛症候群患者治疗疼痛,现处III期临床试验阶段; AXS-05,用于治疗阿兹海默症患者震荡及难治型忧郁症; AXS-02,(对,也是AXS-02,不过不同的开发方向)用于治疗膝骨关节炎及慢性下背疼痛; AXS-06,用于治疗慢性疼痛疾病,处于临床前阶段。Axsome Therapeutics, Inc.个股新闻:2019年1月7日,Axsome Therapeutics股价飙涨+161.60%,源于其AXS-05治疗重度抑郁症的第 II 阶段实验结果。第 II 阶段的研究结果显示,Axsome Therapeutics公司向患有严重抑郁症的患者采用了两种不同剂量的AXS-05,范围从中度到重度。 这包括45mg右美沙芬或105mg活性对照安非他酮,每天两次,持续六周。来自第 ii 阶段试验的好消息是AXS-05能够满足其主要目标:在Montgomery-Åsberg Depression Rating Scale(蒙哥马利抑郁评定量表)上减少了17.2分,相比之下,服用安非他酮的对照患者在相同剂量下减少了12.1分。

交易日期 交易人 职位 类型 交易份额 价格
2017-03-28 Jeffs (Roger A Ph.D.) Director Buy 7344 3.67
2017-03-28 Jeffs (Roger A Ph.D.) Director Buy 35194 4.95
2015-12-22 Kaye (Randall E) Officer Buy 1000 9.03
2015-11-23 Saad (Mark E) Director Buy 3502 5.94
2015-11-23 Kaye (Randall E) Officer Buy 5022 5.40
2015-11-23 Jeffs (Roger A Ph.D.) Director Buy 4374 5.94
2015-11-23 Ames (Constance) Officer Buy 4358 5.94
2015-11-23 Coleman (Mark H) Director Buy 243750 5.40
2015-11-23 Coleman (Mark H) Director Buy 140672 5.94
2015-11-23 Coleman (Mark H) Director Buy 180526 5.94
2015-11-23 Tabuteau (Herriot M.D.) Chief Executive Officer Buy 7229 5.94

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Royce & Associates, LP 182400 0.55% -150000 -45.13% 2019-03-31
RTW INVESTMENTS, LLC 595635 1.79% 595635 -- 2019-03-31
Vanguard Investments Australia Ltd 657414 1.97% 85669 14.98% 2019-07-31
Millennium Management LLC 763974 2.29% 455172 147.40% 2019-03-31
BlackRock Fund Advisors 838536 2.52% 4542 0.54% 2019-07-31
Vanguard Group Inc 901787 2.71% 563083 166.25% 2019-03-31
VHCP Management III, LLC 1068044 3.21% 1068044 -- 2019-03-31
Alethea Capital Management, LLC 1140394 3.42% 231965 25.53% 2019-03-31
Baker Bros Advisors LP 1200000 3.60% 1200000 -- 2019-03-31
VHCP Management II, LLC 571956 1.72% 571956 -- 2019-03-31
Invesco Advisers, Inc. 547975 1.65% 96424 21.35% 2019-07-31
SSGA Funds Management Inc 211911 0.64% 12960 6.51% 2019-07-31
PURA VIDA INVESTMENTS, LLC 213645 0.64% 213645 -- 2019-03-31
LAURION CAPITAL MANAGEMENT LP 219000 0.66% 219000 -- 2019-03-31
EAM Investors, LLC 227241 0.68% 227241 -- 2019-03-31
Ghost Tree Capital, LLC 310000 0.93% 310000 -- 2019-03-31
Stifel Financial Corp 404145 1.21% -- -- 2019-03-31
AllianceBernstein L.P. 404488 1.21% 20780 5.42% 2019-07-31
BlackRock Inc 465587 1.40% 401538 626.92% 2019-03-31
RA Capital Management, LLC 3293789 9.89% 3293789 -- 2019-03-31
Invesco Capital Management LLC 475375 1.43% -4579 -0.95% 2019-06-30
Parallax Volatility Advisers, LLC 167001 0.50% 167001 -- 2019-03-31
Principal Global Investors, LLC 117273 0.35% -16620 -12.41% 2019-05-31
Schonfeld Strategic Advisors LLC 124500 0.37% 124500 -- 2019-03-31
Bridgeway Capital Management, Inc 128000 0.38% 65000 103.17% 2019-03-31
Fidelity Management & Research Company 161134 0.48% 4823 3.09% 2019-05-31
Geode Capital Management, LLC 188410 0.57% 94205 100.00% 2018-12-31
Endurant Capital Management LP 209195 0.63% 114010 119.78% 2018-12-31
Sio Capital Management, LLC 380812 1.14% -35646 -8.56% 2018-12-31
SEI Investments Management Corp 113856 0.34% -18796 -14.17% 2019-05-31
Oxford Asset Management, LLC 73713 0.22% 73713 -- 2018-12-31
Jacobs Levy Equity Management, Inc. 74265 0.22% -9900 -11.76% 2019-03-31
Dreyfus Corporation 59540 0.18% -32327 -35.19% 2019-04-30
Point72 Asset Management, L.P. 250000 0.75% 250000 -- 2018-12-31
Columbia Mgmt Investment Advisers, LLC 60864 0.18% -81812 -57.34% 2019-03-31
Northern Trust Investments Inc 44220 0.13% 4686 11.85% 2019-03-31
Mariner Wealth Advisors, LLC 41525 0.12% -- -- 2018-12-31
Spark Investment Management LLC 40900 0.13% 40900 -- 2018-12-31
JPMorgan Chase & Co 40698 0.12% -40980 -50.17% 2018-09-30
Fidelity Management and Research Company 416252 1.27% -565698 -57.61% 2018-09-30
Worth Venture Partners, LLC 40000 0.13% 40000 -- 2018-09-30
J.P. Morgan Securities Inc 40698 0.14% -40980 -50.17% 2018-09-30
Opus Point Partners Management, LLC 120150 0.40% -13350 -10.00% 2018-09-30
FMR Inc 416252 1.40% -565698 -57.61% 2018-09-30
Baldwin Brothers Inc 30551 0.10% 5000 19.57% 2018-09-30
Fidelity SelectCo, LLC 375452 1.26% -273163 -42.11% 2018-11-30
Allianz Global Investors GmbH 125670 0.42% -- -- 2018-11-30
JPMorgan Asset Management (Europe) S.¨¤ r.l. 171281 0.57% -791244 -82.21% 2018-11-30
Legg Mason Investment Counsel Inc 404145 1.36% -- -- 2018-06-30
Sabby Management LLC 81159 0.27% 81159 -- 2018-03-31
JP Morgan Asset Management (UK) Ltd 157881 0.53% -1274575 -88.98% 2018-03-31
Royce & Associates, LLC 956000 3.74% 75000 8.51% 2018-03-31
J.P. Morgan Investment Management Inc. 157881 0.62% -1274575 -88.98% 2018-03-30
BlackRock Advisors (UK) Ltd 35600 0.14% -- -- 2018-06-30
Northern Trust Investments N A 30515 0.12% -- -- 2018-06-30
Group One Trading, LP 39084 0.15% 32386 483.52% 2018-03-31
Vassalluzzo Scott J 21592 0.08% -37690 -63.58% 2018-06-30
Walleye Trading LLC 28323 0.11% 28323 -- 2018-03-31
J P Morgan Asset Management (UK) Ltd 157881 0.62% -1274575 -88.98% 2018-03-31
Dynamic Technology Lab Private Ltd 26478 0.10% 26478 -- 2018-03-31
Forbes J M & Co 15066 0.06% -- -- 2017-12-31
Trexquant Investment LP 22911 0.09% 22911 -- 2017-12-31
Goldman, Sachs & Co. 42473 0.17% 42473 -- 2017-12-31
Susquehanna Financial Group, LLLP 68795 0.27% 68795 -- 2017-12-31
Allianz Global Investors 125670 0.49% -- -- 2017-12-31
Renaissance Technologies Corp 48400 0.19% 48400 -- 2017-12-31
Allianz Global Investors U.S. LLC - San Francisco 125670 0.50% -- -- 2017-12-31
Sphera Funds Management Ltd. 501000 2.12% -- -- 2017-09-30
Squarepoint Ops LLC 33600 0.14% 33600 -- 2017-09-30
Element Capital Management LLC 61510 0.26% 61510 -- 2017-06-30
Sunrise Partners LLC 48900 0.21% 48900 -- 2017-06-30
State Street Corp 126222 0.66% 12731 11.22% 2016-09-30
BlackRock Advisors LLC 37940 0.20% -541 -1.41% 2016-09-30
TIAA-CREF Investment Management LLC 32742 0.17% -- -- 2016-09-30
California State Teachers Retirement Sys 23212 0.12% -100 -0.43% 2016-09-30
Northern Trust Asset Management 26413 0.14% 194 0.74% 2016-12-31
Morgan Stanley Smith Barney LLC 19800 0.10% -39817 -66.79% 2016-09-30
BNY Mellon Investment Management 19385 0.10% -- -- 2016-09-30
Charles Schwab Investment Management Inc 17700 0.09% -- -- 2016-09-30
Lombard Odier Asset Management USA Corp 328061 1.71% -13729 -4.02% 2016-09-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BlackRock Extended Equity Market 43113 0.13% -59 -0.14% 2019-06-30
Invesco DWA SmallCap Momentum ETF 137897 0.41% -- -- 2019-07-31
SPDR 195746 0.59% 9160 4.91% 2019-07-31
iShares Russell 2000 Growth ETF 224219 0.67% 3497 1.58% 2019-07-30
Vanguard Extended Market Index Fund 295454 0.89% -2060 -0.69% 2019-06-30
AB Small Cap Growth Portfolio 344590 1.03% 36250 11.76% 2019-06-30
Invesco Health Care Fund 477441 1.43% 105185 28.26% 2019-06-30
iShares Russell 2000 ETF 531357 1.60% 1045 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 652039 1.96% 85700 15.13% 2019-06-30
Principal SmallCap Growth Fund I 123810 0.37% 11650 10.39% 2019-06-30
Royce Low-Priced Stock Fund 114700 0.34% -67700 -37.12% 2019-06-30
Bridgeway Ultra Small Company Market Fd 114000 0.34% 51000 80.95% 2019-03-31
AB Small Cap Core Portfolio 43777 0.13% -15470 -26.11% 2019-06-30
Russell 2000 Index Non-Lendable Fund E 48935 0.15% 48935 -- 2019-06-30
Schwab Small Cap Index Fund 50697 0.15% 50697 -- 2019-06-30
Vanguard Health Care Index Fund 60251 0.18% -650 -1.07% 2019-06-30
iShares Micro-Cap ETF 61977 0.19% -- -- 2019-07-30
Invesco VI Health Care Fund 70534 0.21% 14789 26.53% 2019-06-30
Invesco Global Health Care Fund 91233 0.27% -- -- 2019-04-30
Fidelity 106111 0.32% -- -- 2019-06-30
Invesco DWA Healthcare Momentum ETF 301451 0.91% -- -- 2019-06-30
BNY Mellon Select Managers Sm Cp Gr Fd 37646 0.11% -21373 -36.21% 2019-05-31
Vanguard Instl Total Stock Market Idx Fd 27554 0.08% 4014 17.05% 2019-05-31
SEI Small Cap (SIMT) Fund 29522 0.09% -23204 -44.01% 2019-05-31
Neuberger Berman Small Cap Growth Fund 20500 0.06% -21500 -51.19% 2019-04-30
NT Ext Equity Market Index Fund - L 18786 0.06% 4348 30.11% 2019-03-31
SEI Small Cap Growth (SIMT) Fund 26809 0.08% -- -- 2019-04-30
SEI Small Cap II (SIIT) Fund 28631 0.09% -- -- 2019-04-30
Dreyfus Select Managers Small Cap Gr Fd 59540 0.18% -32327 -35.19% 2019-03-31
VALIC Company I Small Cap Fund 14000 0.04% 14000 -- 2019-02-28
Multi-Manager Small Cap Equity Strat Fd 60864 0.18% -81812 -57.34% 2019-02-28
SEI Small Cap (SIIT) Fund 15014 0.05% -10793 -41.82% 2019-03-31
NT Extended Equity Market Idx Fund - NL 13451 0.04% -- -- 2019-03-31
SEI Catholic Values Equity Fund (SCVT)Fd 13322 0.04% -5024 -27.38% 2019-03-31
State Street U.S. Extended Market Index 13100 0.04% -- -- 2019-03-31
Vanguard Balanced Index Fund 10683 0.03% -- -- 2019-02-28
iShares Core S&P Total US Stock Mkt ETF 11278 0.03% 12 0.11% 2019-03-29
Vanguard US Equity Index Fund 5865 0.02% -- -- 2019-01-31
The Vanguard Total Stock Market Index 4705 0.01% -- -- 2019-01-31
1290 VT Micro Cap Portfolio 3727 0.01% 546 17.16% 2018-12-31
Invesco Wilshire Micro-Cap ETF 4579 0.01% -- -- 2019-01-31
BNY Mellon Market Completion Fund 1104 -- 1104 -- 2018-12-31
Meeder Spectrum Fund 2533 0.01% -- -- 2018-12-31
Invesco All Cap Market Neutral Fund 23550 0.07% -- -- 2018-09-30
Fidelity Advisor -- -- -228263 -100.00% 2018-08-31
JPM Global Healthcare Fund 171281 0.57% -791244 -82.21% 2018-03-31
Royce Smaller-Companies Growth Fund 556000 1.86% -100000 -15.24% 2018-06-30
JPM Global Healthcare Fund UL 171281 0.57% -791244 -82.21% 2018-03-31
Allianz Biotechnologie 125670 0.43% -- -- 2017-12-31
Royce Smaller-Companies Growth Svc 556000 2.12% -100000 -15.24% 2018-06-30
Royce Low Priced Stock Svc 332400 1.27% 32400 10.80% 2018-06-30
Vanguard Extended Market Idx Inv 197614 0.75% -- -- 2018-07-31
Bridgeway Ultra-Small Company Market 88000 0.34% -- -- 2018-06-30
iShares Micro-Cap 43537 0.16% -- -- 2018-09-12
Vanguard Instl Ttl Stk Mkt Idx InstlPls 34549 0.13% -- -- 2018-07-31
Invesco All Cap Market Neutral A 23550 0.09% 23550 -- 2018-06-30
Fidelity Spartan 21511 0.08% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 331550 1.26% -- -- 2018-07-31
Meeder Spectrum 2029 0.01% 209 11.48% 2018-08-31
AXA/Lord Abbett Micro Cap K 3181 0.01% -- -- 2018-07-31
Wilshire Micro-Cap ETF 4671 0.02% -- -- 2018-09-14
iShares Core S&P Total US Stock Mkt 9100 0.03% -- -- 2018-09-12
Vanguard Balanced Index Inv 11687 0.04% -- -- 2018-07-31
Nuveen Small Cap Index I 599 -- -136 -18.50% 2017-03-31
BNY Mellon Market Completion Fund UC1 1118 -- 1118 -- 2017-12-31
Vantagepoint Mid/Small Company Index I 1967 0.01% -- -- 2016-09-30
JPMorgan US Small Company Instl 138200 0.72% 3400 2.52% 2016-12-31
The Vanguard Russell 2000 Growth Index 17729 0.09% -- -- 2016-12-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 26413 0.14% 194 0.74% 2016-12-31
CREF Stock R1 28468 0.15% -- -- 2016-12-31
iShares Russell 2000 Growth 87131 0.42% -- -- 2017-02-07
Schwab Small Cap Index 17700 0.09% -- -- 2016-12-31
AXA 2000 Managed Volatility K 13752 0.07% -- -- 2016-11-30
BlackRock Russell 2000 12851 0.07% 686 5.64% 2016-12-31
BlackRock Russell 2500 12366 0.06% 12366 -- 2016-12-31
TIAA-CREF Small-Cap Blend Idx Inst 11659 0.06% -- -- 2016-12-31
SST Small Cap 3 9300 0.05% -200 -2.11% 2016-12-31
Vanguard Russell 2000 ETF 8108 0.04% 576 7.65% 2016-12-31
LVIP SSgA Small Cap Index Std 8485 0.04% 8100 2103.90% 2016-12-31

Mark E. Saad Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University.
Myrtle S. Potter Myrtle S. Potter is an entrepreneur and businessperson who founded Myrtle Potter & Co. LLC, Myrtle Potter Media, Inc. and Astra Merck, Inc. and who has been the head of 6 different companies. Presently, she is Chairman for Myovant Sciences Ltd. and Chairman at Urovant Sciences Ltd. Ms. Potter is also Chairman-Vant Operation at Roivant Sciences, Inc. and on the board of 11 other companies. In the past Ms. Potter was Chief Executive Officer of Myrtle Potter & Co. LLC, Chief Executive Officer at Chapman Properties, Inc., Chief Executive Officer of Myrtle Potter Media, Inc., Vice President at Merck & Co., Inc., President-US Cardiovascular & Metabolics at Bristol-Myers Squibb Co. and President & Chief Operating Officer for Genentech, Inc. She received an undergraduate degree from The University of Chicago.
Roger A. Jeffs Roger A. Jeffs founded Bull City Select Investments LLC. He is Co-Owner at this company. Dr. Jeffs is also on the board of 6 other companies. In the past he held the position of President, Co-Chief Executive Officer & Director at United Therapeutics Corp., Associate Director-Clinical Research at Amgen, Inc. and Member-Clinical Research at Glaxo Wellcome, Inc. He received an undergraduate degree from Duke University and a doctorate from UNC School of Medicine.
Herriott Tabuteau Dr. Herriott Tabuteau, MD, is Founder at Antecip Capital Management LLC. Dr. Tabuteau began his professional career as an investment banking analyst at Goldman Sachs and subsequently was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Dr. Tabuteau earned his MD from Yale University School of Medicine and his BA in molecular biology and biochemistry from Wesleyan University.
Myrtle S. Potter Myrtle S. Potter is an entrepreneur and businessperson who founded Myrtle Potter & Co. LLC, Myrtle Potter Media, Inc. and Astra Merck, Inc. and who has been the head of 6 different companies. Presently, she is Chairman for Myovant Sciences Ltd. and Chairman at Urovant Sciences Ltd. Ms. Potter is also Chairman-Vant Operation at Roivant Sciences, Inc. and on the board of 11 other companies. In the past Ms. Potter was Chief Executive Officer of Myrtle Potter & Co. LLC, Chief Executive Officer at Chapman Properties, Inc., Chief Executive Officer of Myrtle Potter Media, Inc., Vice President at Merck & Co., Inc., President-US Cardiovascular & Metabolics at Bristol-Myers Squibb Co. and President & Chief Operating Officer for Genentech, Inc. She received an undergraduate degree from The University of Chicago.
Mark L. Jacobson Mark L. Jacobson occupies the position of Secretary & Senior Vice President-Operations at Axsome Therapeutics, Inc. He previously held the position of Director-Corporate Development at Stemline Therapeutics, Inc. He received an undergraduate degree from Iowa State University and a graduate degree from Columbia University.
Mark E. Saad Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University.
Cedric O'Gorman Currently, Cedric O'Gorman is SVP-Clinical Development & Medical Affairs at Axsome Therapeutics, Inc. He previously was Vice President-Medical Affairs for Intra-Cellular Therapies, Inc. He received a doctorate from National University of Ireland and an MBA from The Leonard N Stern School of Business.
Mark Coleman Currently, Mark Coleman is Medical Director at National Spine Center. He is also on the board of Axsome Therapeutics, Inc. and Stimwave Technologies, Inc. and Medical Director-Baltimore Branch at National Spine & Pain Centers Holdings LLC. Mark Coleman received a doctorate from The Johns Hopkins University School of Medicine and an undergraduate degree from Wesleyan University.
Mark E. Saad Currently, Mark E. Saad occupies the position of Chief Operating Officer & Partner at Alethea Capital Management LLC. He is also on the board of Axsome Therapeutics, Inc. and Ra Medical Systems, Inc. He previously was Chief Operating Officer for Global Empire LLC, Chief Financial Officer for Bird Rock Bio, Inc., Chief Financial Officer at Cytori Therapeutics, Inc. and Chief Financial Officer of MacroPore Biosurgery, Inc. (a subsidiary of Cytori Therapeutics, Inc.) and Chief Operating Officer-Global Healthcare Group at UBS Investment Bank (US). He received an undergraduate degree from Villanova University.
Nick Pizzie Presently, Nick Pizzie is CFO & Principal Accounting Officer for Axsome Therapeutics, Inc. He previously occupied the position of Chief Financial Officer & Vice President for Pierre Fabre USA and Senior Finance Director at Immucor, Inc. Mr. Pizzie received an MBA and an undergraduate degree from Rutgers State University of New Jersey.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐